marijuana stocks news

Cara Therapeutics to Announce Second Quarter 2016 Financial Results on August 4, 2016

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m. ET to report second quarter 2016 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 50082596. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

 CLS Holdings USA, Inc. (CLSH) Announces Opening of THC Extraction and Production Facility

CLS Holdings Announces Opening of THC Extraction and Production Facility    CLS…

$MCIG Construction Division Announces Master Distributor Deal With CannaPod

mCig, Inc. Construction Division Announces Master Distributor Deal With CannaPod mCig, Inc.…

Cara Therapeutics, Inc. (CARA) Doses First Patient in Phase 1 Trial of Oral KORSUVA™

Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™…